Anti-fibrotic effects of GLP-1 and GLP-1(9-36) on HF- or HG-incubated cardiomyocytes and cardiac fibroblasts.

Implication of PPARδ. (a) Fibronectin levels in GLP-1 and GLP-1(9-36) pre-treated cardiomyocytes exposed to HF (left) or HG (right). Some cells were also incubated with a PPARδ antagonist (G5797). (b) Pre-treatment of sitagliptin in GLP-1 +/- HF-/HG-stimulated cardiomyocytes. (c) Fibronectin expression was also examined in cardiac fibroblast. *p<0.05 and **p<0.01 vs. control. †p<0.05 and ††p<0.01 vs. HF or HG. §p<0.05 vs. HF+GLP-1 or HG+GLP-1.